Sanofi-Aventis's Q1 boosted by emerging markets and H1N1 as hopes for Eloxatin growth return
This article was originally published in Scrip
Executive Summary
A 41% rise in sales in emerging markets (at constant exchange rates) and an even stronger growth in vaccine sales helped to push Sanofi-Aventis's net sales up by 4% (as reported; + 6% at constant exchange rates) to €7.4 billion in the first quarter.